Ikuo Nishimoto Appl. No. 10/088,699 Amdt. dated December 23, 2004 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group

## Amendments to the Specification:

Please replace the paragraph beginning at page 11, line 15, with the following amended paragraph:

There is no particular limitation in organs from which tissues of the affected area or its vicinity are collected, and any organ or tissue in which showing cell death is the as a clinical symptom of the disorder (for example, neuronal tissues in the case of neuronal disorders, lung tissues in the case of lung disorders) may be used. If a cDNA library is prepared from these tissues and cells, that library has condensed mRNA expressed in cells that have survived in the affected tissue. Furthermore, polypeptides of interest can be extracted according to standard methods known in the art from the tissues and cells.

Please replace the paragraph beginning at page 11, line 25, with the following amended paragraph:

When a difference in the clinical symptoms is observed in an affected area or its vicinity, samples are preferably prepared from tissues or cells that are as near to the affected area as possible, and those that have slight clinical symptoms. It is also preferable to prepare samples from tissues or cells collected from the normal or nearly normal parts present in the affected organ, independent of the affected area. Such cells may be high in the expression level of disorder suppressor genes compared to other cells, so a highly efficient screening of disorder suppressor genes or polypeptides can be done. Slight clinical symptoms means that, in a disordered organism, the level of symptoms in a particular area is slight compared to the most severely affected area. When multiple symptoms are seen in association with the disorder, at least any one of them may be compared. For example, in organs or tissues in which showing cell death occurs as the a pathological feature of a disorder, RNA is extracted from areas in which cells efficiently survive. For example, when a severe symptom is observed in the cranial frontal cortex while the symptom in the occipital cortex or cerebellum is relatively slight, samples can

Ikuo Nishimoto PATENT

Appl. No. 10/088,699 Amdt. dated December 23, 2004 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group

be prepared from the latter tissues. In the example of this invention, for example, cDNA library has been constructed from occipital lobe where there is practically no neuronal damage within the cerebrum, a principal site of neuronal death in AD. Similarly, in other disorders, RNA can be extracted from cells in the affected area or its vicinity to construct cDNA library.